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ABSTRACT
Objective: To examine the long-term (three or more
years) effectiveness of the volunteer-delivered
Complete Health Improvement Program (CHIP)
intervention.
Design: Cohort study.
Setting: Hawera, New Zealand.
Participants: Of the total cohort of 284 individuals
who self-selected to complete the CHIP lifestyle
intervention between 2007 and 2009, 106 (37% of the
original cohort, mean age=64.9±7.4 years, range 42–
87 years; 35% males, 65% female) returned in 2012
for a complimentary follow-up health assessment
(mean follow-up duration=49.2+10.4 months).
Intervention: 30-day lifestyle modification programme
(diet, physical activity, substance use and stress
management) delivered by volunteers in a community
setting.
Main outcome measures: Changes in body mass
index (BMI), systolic blood pressure (SBP) and diastolic
blood pressure (DBP), fasting plasma glucose (FPG),
total cholesterol (TC), low-density lipoprotein (LDL),
high-density lipoprotein (HDL) and triglycerides (TG).
Results: After approximately 4 years, participants with
elevated biometrics at programme entry maintained
significantly lowered BMI (−3.2%; 34.8±5.4 vs
33.7±5.3 kg/m2, p=0.02), DBP (−9.4%; 89.1±4.1 vs
80.8±12.6 mm Hg, p=0.005), TC (−5.5%; 6.1±0.7 vs
5.8±1.0 mmol/L, p=0.04) and TG (−27.5%; 2.4±0.8 vs
1.7±0.7 mmol/L, p=0.002). SBP, HDL, LDL and FPG were
not significantly different from baseline. Participants with
elevated baseline biometrics who reported being compliant
to the lifestyle principles promoted in the intervention
(N=71, 67% of follow-up participants) recorded further
reductions in BMI (−4.2%; 34.8±4.5 vs 33.4±4.8 kg/m2,
p=0.02), DBP (−13.3%; 88.3±3.2 vs 77.1±12.1 mm Hg,
p=0.005) and FPG (−10.4%; 7.0±1.5 vs 6.3±1.3 mmol/L,
p=0.02).
Conclusions: Individuals who returned for follow-up
assessment and entered the CHIP lifestyle intervention with
elevated risk factors were able to maintain improvements in
most biometrics for more than 3 years. The results suggest
that the community-based CHIP lifestyle intervention can be
effective in the longer term, even when delivered by
volunteers.
INTRODUCTION
The burden of chronic diseases, including car-
diovascular disease, diabetes and cancer, repre-
sents a major health challenge worldwide.1 2
Deaths from chronic diseases are projected to
increase by 15% by 2020.1 Unhealthy lifestyle
is recognised as one of the major risk factors
of chronic diseases1 and lifestyle interventions
have been shown to be efficacious for their
primary, secondary and early tertiary preven-
tion.3–8 Consequentially, lifestyle interventions
are attracting increasing attention for man-
aging the burgeoning rise of chronic disease.
While the merits of lifestyle interventions
for managing chronic diseases are acknowl-
edged, concerns exist regarding recidivism
and cost. Health behaviour decay is com-
monly observed in weight loss interventions,
with long-term adherence to dietary modifi-
cations typically only achieved by a small pro-
portion of individuals.9 10 Notwithstanding,
the Diabetes Prevention Program has shown
meaningful reductions in body mass for up
to 10 years after programme entry.11 With
regard to cost, lifestyle interventions are
often resource intensive and hence expen-
sive. Residential programmes, while demon-
strating a high level of efficacy in the short
Strengths and limitations of this study
▪ Long-term appraisal of a lifestyle intervention
programme.
▪ This study compares favourably with other pro-
fessionally delivered non-Complete Health
Improvement Program (CHIP) lifestyle interven-
tions, for example, Diabetes Prevention Program.
▪ Small sample size.
▪ Possible selection bias in the follow-up group
with 37% returning for long-term follow-up.
▪ Compliance to lifestyle behaviours was inad-
equately measured.
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term, are especially cost prohibitive for many individuals.
However, an increasing number of community-based
interventions are becoming available. Recently, an adap-
tation of the Diabetes Prevention Program, utilising
community health workers in community settings, was
shown to be effective in reducing and maintaining
reductions in weight, waist circumference and various
diabetes indices 2 years after programme entry.12
The Complete Health Improvement Program (CHIP)
is an intensive, community-based lifestyle intervention
that has demonstrated significant short-term benefits for
the management of a number of chronic diseases.13–16
The CHIP intervention has been delivered by both
health professionals17 18 and trained volunteers.7 8 The
aim of this study was to examine the long-term effective-
ness of volunteer-delivered CHIP interventions which
can be facilitated inexpensively.
METHODS
The study targeted a rural community in New Zealand
where 30-day CHIP interventions have been delivered by
a team of volunteers since 2007. The volunteers had
undergone 2 days of training to develop group facilita-
tion skills and then been equipped with the comprehen-
sive CHIP resource package that included: a curriculum
guide for programme delivery, 16 prerecorded educa-
tional lectures presented by qualified experts, a cook-
book and participant textbook and journal. The role of
the volunteer director was to organise and facilitate the
proceedings of the group sessions, not to educate.
All 323 individuals, who had previously completed the
CHIP intervention, were invited, by letter, to participate
in a follow-up study, irrespective of their outcomes at
30 days. The letter included information detailing the
intent of the study, as well as a complementary follow-up
medical assessment and a form for the participant to
provide informed consent. Though the purpose of the
study was to look at the long-term effects of the pro-
gramme (3+years) it was considered ethical to offer a
follow-up health check to all the participants. Of the 192
that replied (59% response rate), 142 consented to par-
ticipate; 50 did not. On the designated day for the study,
130 returned for the follow-up assessment. Of these 130
individuals, 106 (age=64.9±7.4 years, range 42–87 years)
who had completed the intervention 3 or more years
previously (mean=49.2±10.4 months, range=3–5 years)
were included in this study. As 284 of the original cohort
of 323 participants had completed the intervention 3 or
more years previously, the response rate for this study
was 37%.
The 30-day group-based CHIP intervention, previously
described,7 8 had encouraged and supported the partici-
pants to move towards a low-fat, plant-based diet ad
libitum, with emphasis on the whole-foods consumption
of grains, legumes, fruits and vegetables. The pro-
gramme had also encouraged participants to engage in
30 min of moderate-intensity physical activity daily and
practice stress management techniques. Following com-
pletion of the programme, a monthly support group was
offered to the participants to reinforce lifestyle behav-
ioural changes, and build a network of support and
ongoing education, although it was not considered part
of the intervention. The follow-up study was not planned
at the time the participants enrolled in their respective
CHIPs and so participants were not advised of this even-
tuality. Invitations were extended to all participants to
attend the follow-up study, regardless of whether or not
they chose to attend the monthly support meetings. The
same team of volunteer facilitators had delivered all
the CHIP interventions in a uniform manner, utilising
the programme resources provided.
At programme entry, 30 days and follow-up (approxi-
mately 4 years), the participants’ height, weight and
blood pressure (BP) were taken by registered nurses,
and fasting (12 h) blood samples were collected by
trained phlebotomists and analysed by a local pathology
laboratory. Blood samples were analysed for total choles-
terol (TC), low-density lipoprotein (LDL), high-density
lipoprotein (HDL), triglycerides (TG) and fasting
plasma glucose (FPG) levels. At follow-up, participants
were also asked to complete a questionnaire that
assessed their compliance with lifestyle principles advo-
cated by the CHIP intervention. Participants were also
asked about their attendance at the postintervention
monthly support meetings.
The data were analysed using IBM Statistics (V.19) and
expressed as mean±SD. The extent of changes (per cent
and mean with 95% CIs) from baseline to postintervention
(30 days) and follow-up (mean=49 months) were assessed
using analysis of variance (repeated measures). We have
previously shown that participants who make the greatest
improvements in their biometrics during the CHIP inter-
vention are those with the highest baseline levels.7 Hence,
the participants were stratified by normal or elevated base-
line biometric levels. Cut-points for the biometrics
included in the metabolic syndrome assemblage, as
described by Alberti et al19 were used: raised BP (systolic
blood pressure (SBP) ≥130 mmHg and/or diastolic
blood pressure (DBP) ≥85 mmHg), elevated FPG
(≥5.5 mmol/L), increased TG (≥1.7 mmol/L), decreased
HDL (<1.03 mmol/L in men and <1.3 mmol/L in
women) and waist circumference indicative of central
obesity. As waist circumference was not measured in this
study, body mass index (BMI) >30 kg/m2 was used as a sur-
rogate, as suggested by the International Diabetes
Federation (IDF, 2006). Cut-points for TC (≥5.2 mmol/L)
and LDL (≥2.6 mmol/L), not part of the suite of meta-
bolic syndrome risk factors, were taken from the National
Cholesterol Education Program Adult Treatment Panel III
guidelines.20 Pearson’s χ2 test was used on all demographic
data variables, in order to investigate trends between parti-
cipants who returned for follow-up and those who did not.
Independent t tests were used to compare baseline bio-
metrics. The relationships between nominal variables
likely to be associated with CHIP compliance were
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examined using Spearman’s rank-order correlation (ρ)
with two-tailed tests of significance. Participants were asked
to what extent they adopted the principles promoted in
the CHIP intervention since completing the programme
and a dichotomous variable was created: compliant (‘all’
or ‘most of principles’) and non-compliant (‘a few’ or
‘none of principles’). For all analyses, results were consid-
ered significant at p<0.05.
RESULTS
Significant improvements in all biometrics were observed
over the 30-day intervention for 106 participants who
returned for the follow-up assessment (table 1), which is
consistent with other studies of the 30-day effectiveness of
the CHIP intervention.7 8 However, the primary interest
of this study was the longer term sustainability. All biomet-
rics significantly increased from programme completion
to follow-up (table 1). However, weight was the only bio-
metric in which a net improvement was sustained in the
long term. Participants were able to maintain an average
1.6% decrease in body weight over the long term com-
pared to their weight at programme entry. On the other
hand, following programme completion, SBP increased
resulting in a net 4.2% increase from baseline to
follow-up.
There were no significant differences between the par-
ticipants who did and did not undergo the 3-year to
5-year follow-up testing in baseline age (60.6 vs
58.4 years, p=0.07), gender (35.2% vs 34.6% men,
p=0.92), marital status (90% vs 80% married, p=0.18)
and smoking status (70.3% vs 68.8%, p=0.28). Table 1
also shows baseline characteristics of participants who
did and did not attend the 3-year to 5-year follow-up
testing. There were no significant differences between
the participants who did and did not undergo follow-up
testing in SBP, DBP, TC, LDL and HDL. Individuals who
did not attend the follow-up had significantly higher
BMI, TG and FPG at programme entry. There were also
no significant differences between those who did and
who did not attend follow-up in 30-day levels of SBP,
DBP, TC, LDL and FPG (table 1). However, there were
no significant differences in the amount of change
experienced in any of the biometrics during the 30-day
intervention, even for the biometrics that were different
between the groups at baseline.
For all 106 individuals who attended the follow-up, no
significant change in any biometrics was found.
However, when changes in the biometrics were exam-
ined by baseline level of risk, significant decreases in
several biometrics were observed (table 2). Participants
with elevated BMI, DBP, TC and TG at programme entry
had significantly lowered levels of these biometrics at
the 49-month follow-up (table 2). Conversely, follow-up
levels of BP, LDL and FPG increased above baseline
levels for participants who started the programme with
normal levels (table 2).
Of the 106 CHIP participants who returned for
follow-up assessments 71 (67%) reported being compli-
ant to the lifestyle principles following completion of
the 30-day programme. However, no compliance infor-
mation was recorded for the original cohort who did
not attend the follow-up assessment. Participants who
reported being compliant were 2.8±5.8 kg (95% CI
−4.48 to −1.11; p<0.001) lighter at follow-up compared
to programme entry whereas the non-compliant partici-
pants had gained 1.8±7.0 kg (95% CI −1.27 to 4.82;
p=0.46), amounting to a change difference of almost
5 kg between the groups (p=0.001). The compliant and
non-compliant groups were further analysed according
to baseline biometric risk levels (table 3). Similar trends
can be observed in tables 2 and 3; however, compliant
individuals who entered the programme at elevated risk
had even greater improvements in BMI, DBP and FPG
(table 3). Notably, compliant participants with elevated
BMI at programme entry weighed 4.9±7.2 kg (95% CI
−8.10 to 1.62) less at 3–5 years of follow-up (p=0.002).
Compliant participants with elevated baseline biometrics
had significant reductions at follow-up for 3 of the 5 cri-
teria for the metabolic syndrome. Conversely, compliant
participants who started the programme with normal
baseline levels reported increases at follow-up in several
biometrics (table 3). Analyses of the non-compliant par-
ticipants by baseline risk levels were not possible due to
small numbers.
Postintervention compliance was positively correlated
with attendance at the monthly support meetings
(ρ=0.402, p<0.001). Although only 26 of the study parti-
cipants reported attending these meetings, all of these
individuals reported being compliant to the lifestyle
principles presented in the programme. These indivi-
duals had a 3.5±4.8 kg (95% CI −5.95 to −1.12; p=0.003)
weight loss at follow-up but this was not significantly dif-
ferent (p=0.50) to the compliant individuals who did
not attend the monthly support meetings (2.6±6.2 kg,
95% CI −4.92 to −0.24; p=0.03). While only few in
number (N=13), participants who attended the support
meetings and entered the programme with elevated
BMI had a highly significant weight loss at follow-up (5.6
±5.3 kg, 95% CI −9.71 to −1.46; p=0.008). Yet this was
once again not significantly different (p=0.82) to the
compliant individuals who entered the programme with
elevated BMI but did not attend the support meetings
(N=18; 5.0±8.2 kg, 95% CI −10.11 to 0.11; p=0.06).
Attendance at monthly support meetings was not
related to participating in the CHIP intervention with a
spouse or friend (ρ=0.008, p=0.93): equal proportions of
participants who attended with a partner either did or
did not attend support meetings (69.2% vs 68.4%,
p=0.93). Similarly, attending the CHIP intervention with
a partner was not related to reported compliance at
follow-up (ρ=0.17, p=0.08): there was no difference in
the proportion of individuals who participated with a
partner who reported being compliant or not compliant
(73.2% vs 55.9%, p=0.08).
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Table 1 Baseline biometrics and changes from baseline for participants who attended long-term follow-up (n=106) and those who did not (n=178)
Biometric
Attendance at
follow-up N Baseline 30 days
Mean change 30 days
(95% CI)
Per cent
change
3–5 years of
follow-up
Mean change 3–
5 years (95% CI)
Per cent
change†
Weight (kg) Attended 106 83.42±17.05 79.63±15.93 −3.79 (−4.20 to −3.38) −4.5** 82.12±16.17 −1.30 (−2.84 to 0.24) −1.6*
Did not attend 178 91.14±19.1‡ 87.36±18.18§ −3.78¶ (−4.12 to −3.44) −4.1**
BMI (kg/m2) Attended 106 30.07±5.57 28.72±5.28 −1.35 (−1.49 to −1.21) −4.5** 29.78±5.24 −0.29 (−0.84 to 0.25) −1.0
Did not attend 178 32.92±6.56†† 31.57±6.30§ −1.35¶ (−1.47 to −1.24) −4.1**
SBP (mm Hg) Attended 106 130.32±13.05 123.00±11.42 −7.32 (−9.48 to −5.17) −5.6** 135.82±14.98 5.50 (1.95 to 9.05) 4.2**
Did not attend 178 132.92±15.55 125.98±13.88 −6.94¶ (−9.82 to −5.05) −5.2**
DBP (mm Hg) Attended 106 76.92±10.30 73.41±10.47 −3.51 (−5.46 to −1.56) −4.6* 78.40±11.60 1.48 (−0.79 to 3.76) 1.9
Did not attend 178 77.36±11.34 73.04±10.45 −4.32¶ (−5.81 to −2.83) −5.6**
TC (mmol/L) Attended 106 5.35±1.04 4.33±0.99 −1.01 (−1.13 to −0.90) −18.9** 5.31±1.19 −0.04 (−0.29 to 0.21) −0.7
Did not attend 178 5.27±1.11 4.31±1.01 −0.96¶ (−1.05 to −0.86) −18.2**
HDL (mmol/L) Attended 106 1.35±0.32 1.23±0.28 −0.12 (−0.15 to −0.09) −8.7** 1.31±0.33 −0.04 (−0.10 to 0.10) −3.3
Did not attend 178 1.26±0.34 1.13±0.28‡‡ −0.13¶ (−0.16 to −0.11) −10.3**
LDL (mmol/L) Attended 106 3.36±0.94 2.56±0.86 −0.80 (−0.90 to −0.70) −23.7** 3.39±1.01 0.03 (−0.19 to 0.26) 1.0
Did not attend 178 3.26±0.97 2.51±0.85 −0.75¶ (−0.83 to −0.66) −23.0**
TG (mmol/L) Attended 106 1.41±0.74 1.22±0.61 −0.18 (−0.29 to −0.08) −13.1* 1.32±0.64 −0.08 (−0.25 to 0.09) −5.9
Did not attend 178 1.63±0.84‡ 1.47±0.66‡‡ −0.16¶ (−0.25 to −0.06) −9.8*
FPG (mmol/L) Attended 106 5.72±1.07 5.36±0.65 −0.37 (−0.50 to −0.23) −6.4** 5.65±0.95 −0.07 (−0.27 to 0.13) −1.3
Did not attend 178 6.10±1.86‡ 5.55±1.10 −0.55¶ (−0.77 to −0.33) −9.0**
**p<0.001; *p<0.05.
†% change from baseline.
‡Difference in baseline between those who attended follow-up and those who did not at p<0.05 level of significance.
§Difference at 30 days between those who attended follow-up and those who did not at p<0.001 level of significance.
¶Difference in amount of change between those who attended follow-up and those who did not at p>0.05 level of significance.
††Difference in baseline between those who attended follow-up and those who did not at p<0.001 level of significance.
‡‡Difference at 30 days between those who attended follow-up and those who did not at p<0.05 level of significance.
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure;
TC, total cholesterol; TG, triglyceride.
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Table 2 Changes in biometrics at baseline, 30 days and 3–5 years of follow-up for participants by baseline risk levels (n=106)
Factor Risk level N Baseline 30 days
Per cent change; mean change
(95% CI)
3–5 years of
follow-up
Per cent change; mean change
(95%CI)
BMI (kg/m2) ≤30 62 26.75±2.33 25.58±2.17 −4.4; −1.17 (−1.33 to −1.02)** 27.03±3.01 1.1; 0.28 (−0.34 to 0.90)
>30 44 34.75±5.44 33.15±5.20 −4.6; −1.60 (−1.93 to −1.27)** 33.65±5.28 −3.2; −1.10 (−2.04 to −0.16)*
SBP (mm Hg) <130 46 119.04±8.06 117.89±10.91 −1.0; −1.15 (−4.82 to 2.51) 129.67±14.23 8.9; 10.63 (5.38 to 15.89)**
≥130 60 138.97±8.84 126.92±10.27 −8.7; −12.05 (−15.14 to −8.96)** 140.53±13.49 1.1; 1.57 (−3.04 to 6.17)
DBP (mm Hg) <85 79 72.75±8.25 72.00±10.39 −1.0; −0.75 (−3.20 to 1.70) 77.58±11.23 6.6; 4.84 (2.19 to 7.48)**
≥ 85 27 89.11±4.12 77.52±9.77 −13.0; −11.59 (− 16.15 to −7.03)** 80.78±12.55 −9.4; −8.33 (−14.40 to −2.27)*
TC (mmol/L) <5.2 48 4.41±0.52 3.60±0.64 −18.4; −0.81 (−0.98 to −0.65)** 4.73±1.11 7.3; 0.32 (−0.03 to 0.68)^
≥5.2 58 6.12±0.66 4.94±0.80 −19.2; −1.18 (−1.39 to −0.97)** 5.78±1.04 −5.5; −0.34 (−0.66 to −0.01)*
HDL (mmol/L) ≥1.03 (males);
≥1.3 (females)
72 1.50±0.27 1.34±0.25 −10.5; −0.16 (−0.12 to −0.20) ** 1.40±0.30 −6.7; −0.10 (−0.05 to −0.15)**
<1.03 (males);
<1.3 (females)
34 1.04±0.17 1.00±0.17 −3.4; −0.04 (−0.08 to 0.01) 1.11±0.31 7.2; 0.07 (−0.01 to 0.16)
LDL (mmol/L) <2.6 20 2.07±0.50 1.50±0.40 −27.5; −0.57 (−0.73 to −0.41)** 2.59±0.83 25.2; 0.52 (0.10 to 1.04)*
≥2.6 86 3.66±0.73 2.81±0.74 −23.2; −0.85 (−0.99 to −0.71)** 3.58±0.96 −2.2; −0.08 (−0.32 to 0.16)
TG (mmol/L) <1.7 80 1.09±0.32 1.05±0.37 −3.5; −0.04 (−0.11 to 0.04)* 1.19±0.56 9.6; 0.11 (−0.05 to 0.26)
≥1.7 26 2.39±0.78 1.76±0.87 −26.5; −0.64 (−1.08 to −0.19)* 1.73±0.72 −27.5; −0.66 (−1.09 to −0.23)*
FPG (mmol/L) <5.5 66 5.17±0.29 5.06±0.30 −2.1; −0.11 (−0.21 to −0.01_* 5.29±0.40 2.4; 0.13 (0.03 to 0.22)*
≥5.5 40 6.64±1.26 5.85±0.76 −11.8; −0.79 (−1.14 to −0.43)** 6.24±1.27 −6.0; −0.40 (−0.89 to 0.10)
*p<0.05; **p<0.001; ^p<0.1.
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure;
TC, total cholesterol; TG, triglyceride.
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Table 3 Changes in biometrics at baseline, 30 days and 3–5 years of follow-up by baseline level among self-reported compliant participants (n=71)
Factor Risk level N Baseline 30 days
Per cent change; mean change
(95%CI)
3–5 years of
follow-up
Per cent change; mean change
(95%CI)
BMI (kg/m2) ≤30 39 26.51±2.50 25.33±2.34 −4.5; −1.18 (−1.40 to −0.97** 26.22±2.75 −1.1; −0.29 (−0.92 to 0.24)
>30 32 34.82±4.54 33.29±4.24 −4.4; −1.53 (−1.92 to −1.15** 33.35±4.77 −4.2; −1.47 (−2.67 to −0.27)*
SBP (mm Hg) <130 35 119.00±8.78 116.94±11.65 −1.7; −2.06 (−6.58 to 2.47) 127.91±12.91 7.5; 8.91 (3.54 to 14.29)*
≥130 36 138.50±8.39 127.33±9.09 −8.1; −11.17 (−14.79 to −7.55)** 140.28±14.83 1.3; 1.78 (−4.74 to 8.29)
DBP (mm Hg) <85 55 72.93±8.65 71.60±10.84 −1.8; −1.33 (−4.31 to 1.66) 78.31±11.61 7.4; 5.38 (2.53 to 8.23)**
≥85 16 88.31±3.16 76.88±7.85 −13.0; −11.44 (−16.94 to −5.93)** 77.13±12.13 −12.7; −11.19 (−19.10 to −3.28)*
TC (mmol/L) <5.2 31 4.34±0.55 3.61±0.65 −16.9; −0.73 (−0.92 to −0.55)** 4.65±1.07 7.1; 0.31 (−0.15 to 0.76)
≥5.2 40 6.10±0.57 4.95±0.78 −18.8; −1.15 (−1.40 to −0.90)** 5.78±0.95 −5.3; −0.33 (−0.69 to 0.04)^
HDL (mmol/L) ≥1.03 (males);
≥1.3 (females)
51 1.51±0.26 1.35±0.23 −10.3; −0.16 (−0.21 to −0.10)** 1.40±0.29 −7.4; −0.11 (−0.19 to −0.03)*
<1.03 (males);
<1.3 (females)
20 1.05±0.16 1.03±0.18 −2.3; −0.02 (−0.09 to 0.05) 1.06±0.23 0.5; 0.01 (−0.09 to 0.10
LDL (mmol/L) <2.6 15 2.03±0.57 1.45±0.44 −28.9; −0.59 (−0.78 to −0.39)** 2.63±0.95 29.4; 0.60 (−0.10 to 1.30)
≥2.6 56 3.68±0.67 2.89±0.72 −21.6; −0.80 (−0.96 to −0.63)** 3.59±0.93 −2.5; −0.09 (−0.36to 0.17)
TG (mmol/L) <1.7 52 1.03±0.32 0.99±0.31 −3.5; −0.04 (−0.13 to 0.06) 1.13±0.62 10.1; 0.10 (−0.12 to 0.32)
≥1.7 19 2.33±0.80 1.69±0.88 −27.3; −0.64 (−1.10 to −0.18)* 1.71±0.76 −26.8; −0.62 (−1.10 to −0.15*
FPG (mmol/L) <5.5 48 5.15±0.30 5.06±0.30 −1.9; 0.10 (−0.23 to 0.03) 5.32±0.39 3.3; 0.17 (0.05 to 0.28)*
≥5.5 23 7.04±1.49 5.96±0.83 −15.4; −1.09 (−1.62 to −0.55)** 6.31±1.33 −10.4; −0.74 (−1.36 to −0.11)*
*p<0.05; **p<0.001; ^p<0.1.
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure;
TC, total cholesterol; TG, triglyceride.
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DISCUSSION
Substantial reductions in selected chronic disease risk
factors were achieved within the 30-day CHIP lifestyle
intervention, and importantly, the majority of these
reductions were maintained 3 or more years among
those participants who returned for follow-up assessment
and entered the programme with elevated biometrics.
These findings are particularly noteworthy as the inter-
vention was administered by trained volunteers, which is
a very cost-effective mode for delivering lifestyle
interventions.
Strengths of this study and comparison with other studies
The 30-day results observed in this study are comparable
to other studies of the CHIP intervention delivered by
health professionals as well as trained volunteers in the
USA and Australasia.7 8 15 Longer term studies of partici-
pants in two professionally presented CHIP interven-
tions have separately shown decreases in most biometrics
at 6 and 12 months of follow-up.17 18 However, the
present study is the longest term appraisal of the CHIP
intervention, and the only study of the sustainability of
improvements achieved following participation in
volunteer-delivered programmes. The results in this
study are similar in magnitude to those observed in a
professionally delivered randomised control trial in
which the participants entered the programme with
much higher levels of BMI, DBP, TC, TG and FPG than
the participants in this study.21
The results of this study also compare favourably to
other professionally delivered lifestyle interventions.22–24
One of the goals of the Diabetes Prevention Programme
is for a reduction in the body weight of at least 7%.25
Participants in the present study with elevated FPG at
programme entry and who reported being compliant to
the lifestyle principles presented in the CHIP interven-
tion achieved a 5.2% reduction in body weight. This is a
noteworthy outcome given that many of these partici-
pants did not receive ongoing support beyond the
30-day intervention. While ongoing support is recog-
nised as important for minimising health behaviour
decay and maintenance of long-term behavioural
change,26 27 these results suggest that even a
short-lasting lifestyle intervention can have long-lasting
benefits. It is also interesting that attending the postin-
tervention support meetings or participating in the
CHIP intervention with a partner was not related to
postintervention compliance to the lifestyle principles
presented in the programme. Other researchers have
found attending an intervention with a spouse or friend
provides the greatest long-term weight loss.28 29 The out-
comes of this study may have been improved if all parti-
cipants had engaged in ongoing support meetings. Even
so, meaningful improvements in chronic disease risk
factors can be achieved in some individuals without
follow-up support. Strategies, however, for optimising
engagement in lifestyle interventions and increasing
attendance at support meetings need to be explored
further.
Factors contributing to the outcomes
One of the factors that may have contributed to the sus-
tained outcomes observed in this study is the intensive-
ness of the intervention. With the intervention
comprising 16 group sessions, CHIP is more intensive
than most other community-based lifestyle interven-
tions.11 30 31 Studies of the long-term effectiveness of
lifestyle interventions for reducing body weight, lipid
levels, diabetes control and even the regression of ath-
erosclerotic plaques, have shown a clear dose
response.3 5 6 32 However, other interventions in the lit-
erature are typically of 3-months duration, which may be
more desirable for optimal long-term effects than the
30-day CHIP intervention.33 Indeed, there is a need for
further research to determine the most efficacious
dosages of lifestyle interventions with regard to the
number of sessions, programme duration, and the type
and magnitude of lifestyle modifications targeted. While
cost was not a concern in this study as volunteers deliv-
ered the interventions, an understanding of dose
response when applying lifestyle interventions will be an
important consideration for making professionally deliv-
ered programmes cost-effective.
A second factor that may have contributed to the sus-
tained weight loss observed in this study is the unique
eating pattern advocated in the CHIP intervention. Most
weight loss programmes restrict energy intake by limiting
portion sizes or food choices. However, this approach
tends to result in hunger and dissatisfaction with the
eating regime, which contributes to low compliance and
weight regain.34–36 Indeed, weight loss is rarely seen
beyond 2 years of treatment.36 37 The CHIP intervention
allows an ad libitum eating pattern that emphasises the
consumption of plant-based whole foods, which are high
in bulk, and therefore satiating, yet by nature not calor-
ically dense. This ad libitum eating pattern may be more
acceptable to the participant than more restrictive diets.
In fact, Barnard et al38 reported similar levels of accept-
ability of plant-based diets to more traditional diets such
as that recommended by the American Dietetic
Association.
Long-term compliance to prescriptive regimes may also
be more likely when participants enter a programme with
more adverse health parameters. Various studies have
shown that patients with established disease are able to
maintain high levels of adherence to intensive and pre-
scriptive regimes.3 5 6 32 39 Indeed, adherence to struc-
tured regimes has been shown to be more effective for
weight loss than focusing on the macronutrient distribu-
tion.40 41 In the present study, more promising outcomes
were found among at-risk patients who reported being
compliant to the CHIP lifestyle principles and entered the
programme with BMI indicative of obesity, and lipid and
FPG profiles indicative of metabolic syndrome. Likely,
these individuals entered the programme with an elevated
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readiness for change and hence willingness to engage in
the intervention.42
Limitations of the study
There are some limitations of this study that may have
affected the observed results. First, only 37% of partici-
pants accepted the invitation to attend the long-term
follow-up assessment. The results of this analysis are
therefore applicable to those participants who attended
the long-term assessment and are not generalisable to
the original cohort. While this represents a typical
response rate for behavioural interventions,43 it is pos-
sible that the individuals who were more compliant to
the lifestyle principles presented in the intervention
were more inclined to return for retesting, thereby
biasing the outcomes. There were essentially no differ-
ences between those who did and did not return for the
long-term follow-up assessment in their biometrics at
programme entry or the outcomes achieved during the
30-day intervention, so these factors do not appear to
account for the difference in response rate. It is likely
that some of the 121 participants who did not respond
to the invitation could not be contacted as they were no
longer residing in the area were not available at the time
of retesting, or chose not to respond. Some of those
choosing not to return may have done so because they
had not been compliant to the CHIP principles.
Nevertheless, even if the 71 participants who reported
they were compliant comprised all the compliant indivi-
duals from the study sample of 284, this would still rep-
resent 25% of the original cohort. Hence, it is
encouraging that between 25% and 70% of the indivi-
duals who participated in the CHIP intervention
reported being compliant to the lifestyle principles pro-
moted in the programme on an average of 4 years after
the 30-day intervention. Self-reported compliance was a
further limitation of the study. As this was a subjective
measure, variation in adherence to the CHIP lifestyle
principles may have attenuated the long-term outcomes
in the compliant group.
Lifestyle behaviours, such as dietary intake and phys-
ical activity, were also inadequately measured in the
study. Therefore, it was not possible to determine the
extent of changes in lifestyle behaviours the participants
adopted during, and subsequent to, the 30-day interven-
tion. Longitudinal studies need to collect comprehensive
and validated lifestyle measurements and use these con-
sistently throughout the duration of the study. Finally,
the study only involved a small sample. Further investiga-
tion on a larger cohort is warranted.
Implications for public health and future directions
The novel finding of this study is that long-term reduc-
tions in chronic disease risk factors can be achieved
through an intensive, professionally developed lifestyle
intervention delivered by volunteers. Harnessing the
energy of volunteers to facilitate lifestyle interventions
may provide a cost-effective mode for administering
lifestyle interventions. A randomised control trial is
needed to investigate the effectiveness and sustainability
of the lifestyle choices acquired during the CHIP inter-
vention and the associated long-term improvements in
chronic disease risk factors. Further, this study needs to
be replicated in a larger cohort and in other settings, to
ascertain the generalisability of the study results.
Conclusions
The CHIP intervention can achieve significant reduc-
tions in chronic disease risk factors for more than
3 years after programme entry. Further, when delivered
by volunteers, the CHIP intervention is an inexpensive
tool for addressing the public health crisis of chronic
disease that threatens societies, communities, families
and individuals. Further study of the long-term effective-
ness of the CHIP intervention in other cultural settings
is warranted.
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